Search Results - "Knowles, M. A."

FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer by Tomlinson, DC, Baldo, O, Harnden, P, Knowles, MA

“…FGFR3 is frequently activated by mutation in urothelial carcinoma (UC) and represents a potential target for therapy. In multiple myeloma, both over-expression…”
Get full text

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo by Lamont, F R, Tomlinson, D C, Cooper, P A, Shnyder, S D, Chester, J D, Knowles, M A

“…Background: Activating mutations of FGFR3 are frequently identified in superficial urothelial carcinoma (UC) and increased expression of FGFR1 and FGFR3 are…”
Get full text

Mechanisms of FGFR3 actions in endocrine resistant breast cancer by Tomlinson, D.C., Knowles, M.A., Speirs, V.

“…Although endocrine therapy has dramatically improved the treatment of breast cancer therapeutic resistance and tumour recurrence occurs, even in estrogen…”
Get full text

Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner by di Martino, E, L'Hôte, C G, Kennedy, W, Tomlinson, D C, Knowles, M A

“…Although activating mutations of fibroblast growth factor receptor 3 (FGFR3) are frequent in bladder tumors, little information is available on their specific…”
Get full text

Hypoxia regulates FGFR3 expression via HIF-1α and miR-100 and contributes to cell survival in non-muscle invasive bladder cancer by Blick, C, Ramachandran, A, Wigfield, S, McCormick, R, Jubb, A, Buffa, F M, Turley, H, Knowles, M A, Cranston, D, Catto, J, Harris, A L

“…Background: Non-muscle invasive (NMI) bladder cancer is characterised by increased expression and activating mutations of FGFR3. We have previously…”
Get full text

Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer by TOMLINSON, D. C, HURST, C. D, KNOWLES, M. A

“…More than 60% of low-grade non-invasive papillary urothelial cell carcinomas contain activating point mutations of fibroblast growth factor receptor 3 (FGFR3)…”
Get full text

PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs by Ross, R L, Askham, J M, Knowles, M A

“…Although activating mutations of PIK3CA are frequent in urothelial carcinoma (UC), no information is available on their specific effects in urothelial cells or…”
Get full text

PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma by Ross, R L, McPherson, H R, Kettlewell, L, Shnyder, S D, Hurst, C D, Alder, O, Knowles, M A

“…Many urothelial carcinomas (UC) contain activating PIK3CA mutations. In telomerase-immortalized normal urothelial cells (TERT-NHUC), ectopic expression of…”
Get full text

AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K by Askham, J M, Platt, F, Chambers, P A, Snowden, H, Taylor, C F, Knowles, M A

“…The phosphatidylinositol-3-kinase (PI3 kinase)-AKT pathway is frequently activated in cancer. Recent reports have identified a transforming mutation of AKT1 in…”
Get full text

Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer by Teo, M.T.W., Dyrskjøt, L., Nsengimana, J., Buchwald, C., Snowden, H., Morgan, J., Jensen, J.B., Knowles, M.A., Taylor, G., Barrett, J.H., Borre, M., Ørntoft, T.F., Bishop, D.T., Kiltie, A.E.

“…Muscle-invasive bladder cancer (MIBC) can be cured by radical radiotherapy (RT). We previously found tumour MRE11 expression to be predictive of survival…”
Get full text

Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification by Hurst, C D, Tomlinson, D C, Williams, S V, Platt, F M, Knowles, M A

“…E2F3 and CDKAL1 are candidate genes from the 6p22 region frequently amplified in bladder cancer. Expression of E2F3 isoforms (E2F3a and b) and CDKAL1 were…”
Get full text

Putative tumour suppressor gene necdin is hypermethylated and mutated in human cancer by De Faveri, L E, Hurst, C D, Platt, F M, Taylor, C F, Roulson, J-A, Sanchez-Carbayo, M, Knowles, M A, Chapman, E J

“…Background: Necdin (NDN) expression is downregulated in telomerase-immortalised normal human urothelial cells. Telomerase-immortalised normal human urothelial…”
Get full text

Expression of NRG1 and its receptors in human bladder cancer by Forster, J A, Paul, A B, Harnden, P, Knowles, M A

“…Background: Therapies targeting ERBB2 have shown success in the clinic. However, response is not determined solely by expression of ERBB2. Levels of ERBB3, its…”
Get full text

Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16 Rb pathway by CHAPMAN, E. J, HURST, C. D, PITT, E, CHAMBERS, P, AVEYARD, J. S, KNOWLES, M. A

“…The CDKN2A locus is frequently inactivated in urothelial cell carcinoma (UCC), yet how this alteration contributes to bladder tumorigenesis is not known…”
Get full text

The genetics of transitional cell carcinoma: progress and potential clinical application by KNOWLES, M. A

Get full text

Somatic mutation of PTEN in bladder carcinoma by AVEYARD, J. S, SKILLETER, A, HABUCHI, T, KNOWLES, M. A

“…The tumour suppressor gene PTEN/MMAC1, which is mutated or homozygously deleted in glioma, breast and prostate cancer, is mapped to a region of 10q which shows…”
Get full text

What we could do now: molecular pathology of bladder cancer by Knowles, M A

“…There is much information on the genetic alterations that contribute to the development of bladder cancer. Because it is hypothesised that the genotype of the…”
Get full text

Tuberous sclerosis complex (TSC) gene involvement in sporadic tumours by Knowles, M A, Hornigold, N, Pitt, E

“…In tuberous sclerosis patients, inactivation of the tuberous sclerosis complex tumour-suppressor genes TSC1 and TSC2 contributes to the development of a wide…”
Get more information

DBC1 re-expression alters the expression of multiple components of the plasminogen pathway by LOUHELAINEN, J. P, HURST, C. D, PITT, E, NISHIYAMA, H, PICKETT, H. A, KNOWLES, M. A

“…Deleted in bladder cancer 1 (DBC1) is a candidate gene for the bladder tumour suppressor locus at 9q33.1. The function of the gene is currently unknown but a…”
Get full text

Inhibition of double-strand break non-homologous end-joining by cisplatin adducts in human cell extracts by Diggle, C. P., Bentley, J., Knowles, M. A., Kiltie, A. E.

“…The effect of cis-diaminedichloroplatinum(II) (cisplatin) DNA damage on the repair of double-strand breaks by non-homologous end-joining (NHEJ) was determined…”
Get full text